PeptideLabs Logo
PeptideLabs
Quality Documentation
Back to all 64 profiles
Community/research information onlyNot FDA/EMA approvedWADA

Community protocol · BPC-157

BPC-157: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: BPC 157 · Body protection compound 157

Sources checked: 27 August 2026

Important safety and liability notice

This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

BPC-157

Studied preclinically for gastrointestinal tissue and wound repair; clinical benefit and safety are unproven.

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amounts, timing and cycles

Community/research information only

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amount status

Different amounts circulate online; no regulator-confirmed safe or effective dose exists.

Profile evidence level: preclinical.

Timing

Community claims about time of day, fasting windows or training intervals are not validated clinical standards.

No individual recommendation.

Cycle/duration

Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Reconstitution and U-100 conversion

Reconstitution calculator

For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.

Reconstitution calculator

Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.

Concentration

3,333.33 µg/ml

Calculated volume

0.06 ml

U-100 units

6 U

Calculated portions per vial

50

Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.

Mechanism and research questions

Synthetic 15-amino-acid gastric peptide fragment

BPC-157 is classified as “Synthetic 15-amino-acid gastric peptide fragment”. Studied preclinically for gastrointestinal tissue and wound repair; clinical benefit and safety are unproven. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Gastric-protective fragment

Researchers study how a fragment derived from a gastric-protective protein affects stomach lining healing and tissue repair in models. Measures include ulcer size and healing speed in animal models.

02

Cell migration peptide

This studies how a peptide influences the migration of cells toward an injury site, similar to workers rushing to a construction site. Speed and extent of cell migration are measured in lab models.

03

Tissue repair models

Researchers use controlled wound or injury models in cells or animals to study how quickly and completely tissue heals after damage. Measures typically include wound size over time and markers of new tissue formation, similar to photographing a cut each day to see how fast it closes.

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Wound healing anecdotes

People report perceived faster healing of injuries or tendon problems after using certain peptides, usually without a control group or objective measurement. Such individual reports do not establish actual efficacy or safety.

Gut health anecdotes

People report subjectively perceived digestive improvements after using gastric-protective or immune-modulating peptides, usually without objective diagnostics. Such self-observations do not establish a confirmed effect on the gut.

Recovery and injury forums

Personal recovery times after sports injuries while using different repair peptides are compared, often based on subjective pain scales. Such individual courses are influenced by many other factors and do not prove efficacy.

Adverse effects and risk boundaries

  • Many so-called repair peptides lack controlled human studies. Unknown systemic effects, immune reactions, bleeding or vascular effects, and injection-related infection or contamination remain central risks.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • Pregnancy, cancer, active infection, coagulation disorders, planned surgery and relevant immune disease call for especially strict professional assessment or avoidance.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • There is no validated monitoring schedule for unapproved repair peptides. Clinical findings, signs of inflammation, blood count, liver/kidney function and coagulation may be relevant depending on the question.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Preclinical

Evidence is mostly preclinical; human efficacy is not established.

Published evidence

Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.

BPC-157 is derived from a gastric-protective protein, distinguishing it from thymosin beta-4-related fragments such as TB-500.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

WADA 2026

This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile